GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is expanding its investment in the modality.
The gold standard of business intelligence.
GSK's move fuels the industry buzz for the promising anti-tumour modality.
Author's summary: GSK buys Syndivia's ADC for £268m.